Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment

Chiara Camisaschi, Viviana Vallacchi, Chiara Castelli, Licia Rivoltini, Monica Rodolfo

Research output: Contribution to journalArticle

Abstract

Melanoma is an immunogenic tumor and immunotherapy treatment has established an increase in disease-free and overall survival in melanoma patients. However, a complex network of immunosuppressive mechanisms has been demonstrated to occur at the tumor site and in locoregional immune districts, such as sentinel lymph nodes (SLNs). The interplay between tumor cells and the local microenvironment leads to a tumor-driven shaping of the immune response that results in a heterogeneous cellular and molecular composition of tumor infiltrating lymphocytes (TILs). Several studies have reported the potential prognostic value of TILs infiltrating primary tumors and the association of 'immune signature' in SLNs and in melanoma metastases with prognosis and responsiveness to immunotherapeutic approaches. However, a systematic and deeper characterization of the local immunological status of TILs and SLNs is still required to refine melanoma stage classification.

Original languageEnglish
Pages (from-to)643-646
Number of pages4
JournalExpert Review of Molecular Diagnostics
Volume14
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Melanoma
Tumor-Infiltrating Lymphocytes
Recurrence
Neoplasms
Cellular Microenvironment
Therapeutics
Immunosuppressive Agents
Immunotherapy
Disease-Free Survival
Neoplasm Metastasis
Sentinel Lymph Node

Keywords

  • Immunotherapy
  • Melanoma
  • Prognosis
  • Sentinel node
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

@article{462e0d71f8594ccd85184ee4f71bc375,
title = "Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment",
abstract = "Melanoma is an immunogenic tumor and immunotherapy treatment has established an increase in disease-free and overall survival in melanoma patients. However, a complex network of immunosuppressive mechanisms has been demonstrated to occur at the tumor site and in locoregional immune districts, such as sentinel lymph nodes (SLNs). The interplay between tumor cells and the local microenvironment leads to a tumor-driven shaping of the immune response that results in a heterogeneous cellular and molecular composition of tumor infiltrating lymphocytes (TILs). Several studies have reported the potential prognostic value of TILs infiltrating primary tumors and the association of 'immune signature' in SLNs and in melanoma metastases with prognosis and responsiveness to immunotherapeutic approaches. However, a systematic and deeper characterization of the local immunological status of TILs and SLNs is still required to refine melanoma stage classification.",
keywords = "Immunotherapy, Melanoma, Prognosis, Sentinel node, Tumor-infiltrating lymphocytes",
author = "Chiara Camisaschi and Viviana Vallacchi and Chiara Castelli and Licia Rivoltini and Monica Rodolfo",
year = "2014",
doi = "10.1586/14737159.2014.928206",
language = "English",
volume = "14",
pages = "643--646",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment

AU - Camisaschi, Chiara

AU - Vallacchi, Viviana

AU - Castelli, Chiara

AU - Rivoltini, Licia

AU - Rodolfo, Monica

PY - 2014

Y1 - 2014

N2 - Melanoma is an immunogenic tumor and immunotherapy treatment has established an increase in disease-free and overall survival in melanoma patients. However, a complex network of immunosuppressive mechanisms has been demonstrated to occur at the tumor site and in locoregional immune districts, such as sentinel lymph nodes (SLNs). The interplay between tumor cells and the local microenvironment leads to a tumor-driven shaping of the immune response that results in a heterogeneous cellular and molecular composition of tumor infiltrating lymphocytes (TILs). Several studies have reported the potential prognostic value of TILs infiltrating primary tumors and the association of 'immune signature' in SLNs and in melanoma metastases with prognosis and responsiveness to immunotherapeutic approaches. However, a systematic and deeper characterization of the local immunological status of TILs and SLNs is still required to refine melanoma stage classification.

AB - Melanoma is an immunogenic tumor and immunotherapy treatment has established an increase in disease-free and overall survival in melanoma patients. However, a complex network of immunosuppressive mechanisms has been demonstrated to occur at the tumor site and in locoregional immune districts, such as sentinel lymph nodes (SLNs). The interplay between tumor cells and the local microenvironment leads to a tumor-driven shaping of the immune response that results in a heterogeneous cellular and molecular composition of tumor infiltrating lymphocytes (TILs). Several studies have reported the potential prognostic value of TILs infiltrating primary tumors and the association of 'immune signature' in SLNs and in melanoma metastases with prognosis and responsiveness to immunotherapeutic approaches. However, a systematic and deeper characterization of the local immunological status of TILs and SLNs is still required to refine melanoma stage classification.

KW - Immunotherapy

KW - Melanoma

KW - Prognosis

KW - Sentinel node

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84903172686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903172686&partnerID=8YFLogxK

U2 - 10.1586/14737159.2014.928206

DO - 10.1586/14737159.2014.928206

M3 - Article

C2 - 24914691

AN - SCOPUS:84903172686

VL - 14

SP - 643

EP - 646

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 6

ER -